Alamar Biosciences files for proposed Nasdaq IPO

Alamar Biosciences has filed for a proposed Nasdaq IPO.

The company describes itself as: "We are a commercial-stage proteomics company establishing a gold standard in protein detection and analysis. Our proprietary NULISA technology was purpose-built to address the limitations of existing proteomics tools by detecting protein biomarkers at extremely low concentrations in non-invasive biological fluids, such as blood, with ultra-high sensitivity, high specificity, flexible multiplexing, broad dynamic range and seamless automation. We refer to this combination of features as “Precision Proteomics,” and believe it fills a critical gap in the field of advanced proteomics, enabling researchers to establish the relationship between incremental changes in multiplexed protein biomarkers and the clinically meaningful differences in health, disease and drug therapy. Our integrated platform consists of proprietary instruments, consumables and analytical software that is designed to provide scientists with an end-to-end solution to precisely and consistently measure from one to hundreds of low-abundance and difficult-to-detect biomarkers across the continuum of discovery, translational research and ultimately diagnostics."

JPMorgan, BofA Securities, TD Cowen will serve as lead underwriters.

You May Also Be Interested In

• NVIDIA reports 9.3% passive stake in Nebius
• Trump signs proclamations imposing 50% tariffs on some Canadian goods
• AdaptHealth to sell diabetes unit to Cardinal Health for $235M